S*BIO TO COLLABORATE WITH RESEARCH INSTITUTE ON CANCER DRUGS

Singapore-based biotech firm S*BIO announced that it has signed a two-year collaboration agreement with the country's Agency for Science, Technology and Research's (A*STAR) Institute of Molecular and Cell Biology for the discovery and development of multiple compounds for the treatment of cancer. Promising compounds may be further developed by A*STAR's Experimental Therapeutics Centre and S*BIO.

"The collaboration is an excellent strategic fit for S*BIO as we expand our research and development pipeline with novel treatments for cancer," Jan-Anders Karlsson, CEO of S*BIO, said. "We are confident that this new research partnership will further demonstrate S*BIO's capabilities in high-throughput screening, medicinal chemistry, lead finding and lead optimization and build on its proven expertise in the discovery of best-in-class and first-in-class oncology compounds."

S*BIO is focused on the research and clinical development small-molecule oncology drugs, including histone deacetylases and kinases. The company said it intends to become one of the leading biotech firms in Asia Pacific. It has developed a fully integrated state-of-the-art R&D infrastructure and a strong clinical development team.